Patients treated with Altimmune’s investigational GLP-1/glucagon dual receptor agonist saw up to 15.6% weight loss, and nearly a third of those taking the highest dose lost at least 20% of their body weight.
The views of the five doctors, all senior physicians practicing obesity medicine at top universities and hospitals, indicate that Novo’s drug is not likely to have a significant edge based on its heart benefits, even though it will be years before Lilly produces similar cardiovascular data.
The move follows a review that started in July and covered a range of drugs known as GLP-1 receptor agonists, also including Eli Lilly’s Trulicity, Sanofi’s Suliqua, AstraZeneca’s Bydureon and Novo’s Rybelsus and Saxenda.
Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs, a Reuters analysis found.
Authorities in India’s western state of Gujarat are investigating the deaths of three people after they allegedly consumed a contaminated medicinal syrup, according to state government and police officials.
The regulator accepted Karuna Therapeutics’ NDA and set a PDUFA date of September 26, 2024. If approved, it would be the first new mechanism of action to treat schizophrenia in decades, the company contends.
The deal would help boost AbbVie’s plans to expand into the cancer drug market as its top-selling product Humira, a rheumatoid arthritis treatment, faces fierce competition in the United States.
Yesterday Novo Nordisk said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%.
Boehringer Ingelheim is striking a deal to leverage artificial intelligence for some of the hardest to treat cancers. Phenomic AI announced a collaboration agreement with the pharma giant Wednesday.
Cigna is in merger talks with Humana a source familiar with the matter said on Wednesday, potentially marking the latest in a long string of deals aimed at consolidation of the industry.